Jo, Sumin http://orcid.org/0000-0003-1445-9392
Das, Shipra
Williams, Alan
Chretien, Anne-Sophie http://orcid.org/0000-0003-4685-5568
Pagliardini, Thomas
Le Roy, Aude
Fernandez, Jorge Postigo
Le Clerre, Diane
Jahangiri, Billal http://orcid.org/0000-0001-6512-0693
Chion-Sotinel, Isabelle
Rozlan, Sandra
Dessez, Emilie
Gouble, Agnes
Dusséaux, Mathilde
Galetto, Roman
Duclert, Aymeric
Marcenaro, Emanuela http://orcid.org/0000-0003-4103-7566
Devillier, Raynier http://orcid.org/0000-0002-4045-8310
Olive, Daniel http://orcid.org/0000-0003-1299-4113
Duchateau, Philippe http://orcid.org/0000-0002-3491-9168
Poirot, Laurent
Valton, Julien http://orcid.org/0000-0003-0826-5401
Funding for this research was provided by:
Sandra Rozlan is a Cellectis SA employee. Her work has been funding by Cellectis. SA
Emilie Dessez is a Cellectis SA employee. Her work has been funding by Cellectis. SA
Article History
Received: 30 November 2020
Accepted: 24 May 2022
First Online: 30 June 2022
Competing interests
: S.D., S.J., D.L., B.J., I.C.S., A.G., M.D., R.G., J.P.F., A.D., P.D., L.P., and J.V. are Cellectis employees and hold patents related to the engineering process of CAR T cells and TALEN<sup>®</sup> technology. TALEN<sup>®</sup> is a Cellectis’ patented technology. D.O. declares competing interests as being the co-founder and shareholder of Imcheck Therapeutics, Alderaan Biotechnology and Emergence Therapeutics and has research funds from Imcheck Therapeutics, Alderaan Biotechnology, Cellectis SA., and Emergence Therapeutics. A.W., B.J., and M.D. are former Cellectis employee. The remaining authors declare no competing interests.